Today's Date: May 11, 2021
Student-Led Startup Skin Releaf Takes USD 25,000 Top Prize in Standard Chartered 2021 Women in Tech Incubator Competition   •   Unilever's Second Annual Day of Service Gets Sweeter at Vaccine Locations Across the Country   •   National Geographic Documentary Films Partners With Acclaimed Director Dawn Porter in Search of Justice and Peace 100 Years Afte   •   Wells Fargo Joins OneTen Coalition to Hire, Upskill and Advance Black and African American Talent in the U.S.   •   Commvault Celebrates Inclusion of 16 Global Executives to CRN's 2021 Women of the Channel List   •   Paway Celebrates Dog Moms Throughout The Month Of May With Their "Best Dog Mom Challenge"   •   Cadence13 Partners with Globally Renowned Thought Leader, Bestselling Author, and Activist Glennon Doyle for First-Ever Podcast   •   Survey Reveals 8 Out Of 10 Asian Americans Say They Are Discriminated Against And 77% Do Not Feel Respected In The U.S.   •   Merritt Hawkins Survey: New Physicians Getting Fewer Recruiting Offers   •   Investment Banking Veteran and Software Market Strategist Jonathan Price Joins Alegion's Board of Directors   •   AEO Inc. to Report First Quarter 2021 Results on May 26th   •   EquityPlus Completes "4% Floor" $16 Million Bond Sale To Finance Senior Citizen Affordable Housing And Community Wellness Center   •   Susan G. Komen® Welcomes Eight New Leaders in Healthcare, Marketing and Business Operations to Board of Directors   •   Statement - Minister of Veterans Affairs marks National Nursing Week   •   Indigenous Services Canada announces 2021 recipients of the Awards of Excellence in Nursing   •   Accenture and Shiseido Establish Joint Venture to Accelerate Shiseido’s Digital Transformation   •   Global War on Terrorism Memorial Foundation Gets Support From MISSION BBQ American Heroes Cup Campaign   •   Joint statement on the 5th anniversary of Canada's full support for the United Nations Declaration on the Rights of Indigenous P   •   MAËLYS Receives Significant Investment from Norwest    •   BlackNorth Initiative Sponsoring Lori-Ann Green-Walker, Part of the 6th Cohort of the ESG Competent Boards Certificate Program
Bookmark and Share

Gynesonics Announces Publication of SAGE Global Registry Preliminary Results: Real-World Usage Corroborates the Safety and Appli

REDWOOD CITY, Calif. , April 15 /Businesswire/ - Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced the publication of its peer reviewed journal article, “Transcervical Radiofrequency Ablation of Uterine Fibroids Global Registry (SAGE): Study Protocol and Preliminary Results,” in the journal Medical Devices: Evidence and Research. The article reported that of 241 fibroids treated by the Sonata® System, 10 percent were submucous, 52 percent transmural, 28 percent intramural, and 10 percent subserous. Ablated fibroid diameters ranged from <1 cm to >10 cm, with 27 percent of fibroids having maximum diameters >5 cm. Additionally, the preliminary results indicated the Sonata System maintained its established safety profile with very low device-related adverse event and serious procedure-related adverse event rates of 0.6 percent for both measures. These initial results corroborate those from previous clinical trials, as well as more than 1,800 commercial cases worldwide.

“The SAGE registry represents the largest clinical study to date of transcervical fibroid ablation (TFA) and will generate up to 2,500 patient-years of outcomes data,” said Dr. Ladina Christoffel, Head of Gynecology and Obstetrics at the Spital Oberengadin-Schweiz in Samedan, Switzerland. “The real-world outcomes derived from SAGE will further strengthen the existing evidence on the durability of TFA and the Sonata System in providing meaningful relief from uterine fibroid symptoms as well as having important positive clinical and economic implications for patients, physicians and healthcare payers. It is impressive to see the wide range of fibroid types treated, as most of these could not be treated by operative hysteroscopy, and TFA as performed by the Sonata System allows women to avoid the much more invasive options of myomectomy or hysterectomy.”

In the SAGE Registry, eligible patients are adult women (age ≥18 years) with symptomatic uterine fibroids who select TFA for treatment of their fibroids. No limitations are imposed on maximum patient age, fibroid type, fibroid size, prior surgical history, baseline symptom severity, or desire for future fertility. The registry will follow women for 5 years, after which a comprehensive characterization of long-term, real-world outcomes of TFA will be possible.

“We are incredibly pleased to see the SAGE Registry initial results indicate that in real world conditions, women with a very wide range of fibroid types, locations and sizes can be successfully treated with TFA utilizing the Sonata System,” said Taraneh G. Farazi, Ph.D. and Vice President, Clinical Affairs at Gynesonics. “These safety results are completely aligned with data from multiple clinical studies utilizing Sonata. For the millions of women who want to avoid more invasive procedures such as myomectomy or hysterectomy, there is now a safe and effective alternative treatment for their symptomatic fibroids, with excellent long-term results.”

About Sonata System

The Sonata System uses radiofrequency energy to ablate fibroids under real time sonography guidance from within the uterine cavity, utilizing the first and only intrauterine ultrasound transducer. The System includes a proprietary graphical user interface (SMART Guide), enabling the operator to target fibroids and optimize treatment. The Sonata system provides incision-free transcervical access for a uterus-preserving fibroid treatment. This intrauterine approach is designed to avoid the peritoneal cavity. The Sonata System is CE marked and is approved for sale in the European Union and the United States.

About Gynesonics

Gynesonics is a women’s healthcare company focused on advancing women’s health, by developing minimally invasive, incision-free, uterus-preserving, transcervical technologies for diagnostic and therapeutic applications. Gynesonics has developed the Sonata System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids. Gynesonics headquarters is in Redwood City, CA. For more information, go to

STORY TAGS: Medical Devices, Women, Consumer, Health, Clinical Trials, United States, North America, California, Product/Service,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News